|
|
Anika Therapeutics Inc (NASDAQ: ANIK) |
|
Price: $12.1600
$-0.03 
-0.246%
|
| Day's High:
| $12.48
| Week Perf:
| -2.01 %
|
| Day's Low: |
$ 11.69 |
30 Day Perf: |
-11.37 % |
| Volume (M): |
83 |
52 Wk High: |
$ 29.11 |
| Volume (M$): |
$ 1,003 |
52 Wk Avg: |
$20.53 |
| Open: |
$12.11 |
52 Wk Low: |
$11.11 |
|
|
| Market Capitalization (Millions $) |
174 |
| Shares
Outstanding (Millions) |
14 |
| Employees |
187 |
| Revenues (TTM) (Millions $) |
152 |
| Net Income (TTM) (Millions $) |
-57 |
| Cash Flow (TTM) (Millions $) |
-15 |
| Capital Exp. (TTM) (Millions $) |
16 |
Anika Therapeutics Inc
Anika Therapeutics Inc is a global medical technology company that specializes in tissue-medical devices for the regenerative treatment of pain and musculoskeletal conditions. The company is headquartered in Bedford, Massachusetts, USA, and operates in over 30 countries worldwide.
Anika Therapeutics Inc was founded in 1992 by Charles H. Sherwood, Ph.D., and Richard G. Steadman, M.D, with a vision to create and deliver products that could help to promote the healing and recovery of individuals suffering from musculoskeletal injuries or diseases. The company has since grown to become a leading provider of advanced medical devices and therapies, using a range of technologies developed in-house.
The company's core product offering includes a number of tissue implants, including Orthovisc, Monovisc, and Cingal, which are designed to help alleviate the pain and mobility issues experienced by patients with osteoarthritis. These devices, which are made using high-purity hyaluronic acid, are injected into the joint to lubricate and cushion the affected area, providing long-lasting relief.
In addition to these products, Anika Therapeutics Inc also offers a range of other medical devices and solutions, such as the AmnioExcel amniotic membrane product, which is used in wound healing, and the Hyalofast scaffold, which allows for the delivery of cells and growth factors in tissue engineering repair applications.
Anika Therapeutics Inc is proud of its commitment to quality and innovation, investing heavily in research and product development to improve the efficacy and range of its medical solutions. The company has a strong record of innovation, having filed over 100 patents to date, and regularly collaborates with leading medical institutions and industry partners to develop and improve its products.
Overall, Anika Therapeutics Inc offers a diverse range of innovative, high-quality medical solutions designed to address a range of musculoskeletal concerns, improving patient outcomes and quality of life. Its focus on quality, innovation, and collaboration has helped establish it as a leader in the industry, and it continues to grow and expand its product offerings to address the evolving needs of patients worldwide.
Company Address: 32 Wiggins Avenue Bedford 1730 MA
Company Phone Number: 457-9000 Stock Exchange / Ticker: NASDAQ ANIK
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Shares
Published Mon, May 12 2025 9:00 PM UTC
Anika Therapeutics, Inc. Expands Employee Incentives Amid Strategic Refocus Following Financial ChallengesAnika Therapeutics, Inc. (NASDAQ: ANIK), headquartered in Bedford, Massachusetts, has reported a significant development in its efforts to strategically position itself as a leader in osteoarthritis (OA) pain management and regenerative solutions. On May 1, 2025, Anika d...
|
| Management Announcement
Published Thu, Oct 31 2024 11:01 AM UTC
Anika Therapeutics Inc. Strategic Shift Amid Financial ChallengesIn a strategic maneuver aligned with its long-term vision, Anika Therapeutics Inc., a leading name in joint preservation and early intervention orthopedics, has announced a significant update to its business strategy. This includes the sale of its subsidiary, Arthrosurface, and the impending divestment of Par...
|
| Shares
Published Fri, Oct 4 2024 8:01 PM UTC
Anika Therapeutics, Inc. (NASDAQ: ANIK), a forefront leader in joint preservation and early intervention orthopedics, recently announced a significant move reflecting its strategic focus on talent acquisition and retention. On October 1, 2024, the company granted non-statutory stock options covering 6,350 shares of common stock to a newly hired non-executive employee. These ...
|
| Shares
Published Mon, Sep 9 2024 8:45 PM UTC
Anika Therapeutics Grants Inducement Stock Options to Newly Hired Employee
On September 3, 2024, Anika Therapeutics, Inc. announced that it had granted non-statutory stock options covering 2,500 shares of common stock to a newly hired non-executive employee. The grant, made at a per share exercise price of $25.15, was in accordance with the company s 2021 Inducement Plan...
|
| Shares
Published Thu, Aug 15 2024 8:01 PM UTC
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc., a leading global joint preservation company in early intervention orthopedics, recently announced the grant of non-statutory stock options to two newly hired non-executive employees. The options cover a total of 8,850 shares of common stock, with an exercise price of $26.29 per...
|
| Per Share |
Current |
| Earnings (TTM) |
-3.88 $ |
| Revenues (TTM) |
10.63 $
|
| Cash Flow (TTM) |
- |
| Cash |
5.27 $
|
| Book Value |
10.38 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-3.88 $
|
| Revenues (TTM) |
10.63 $ |
| Cash Flow (TTM) |
- |
| Cash |
5.27 $
|
| Book Value |
10.38 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| OEM Channel |
|
 58.05 % |
of total Revenue |
| Commercial Channel |
|
43.84 % |
of total Revenue |
| UNITED STATES |
|
63.72 % |
of total Revenue |
| Europe |
|
22.58 % |
of total Revenue |
| Other Location |
|
15.6 % |
of total Revenue |
| |
On October 31 2024 the Anika Therapeutics Inc provided following guidance
Anika Therapeutics Inc. has recently released its financial results for the third quarter of 2024, alongside an update on the company's fiscal guidance for the current year, concluding on October 31, 2024. The firm has made notable adjustments to its 2024 guidance, primarily in light of strategic shifts within the organization. These changes are largely attributed to the recent sale of Arthrosurface, the anticipated divestiture of Parcus Medical, and challenges faced in the U.S. market regarding osteoarthritis (OA) pain management.
While the company has provided insights into the adjustments made to their future outlook, specific numerical targets or forecasts have not been disclosed. This lack of d...
|
|
|
2.2% 